FDMT
Materials4D Molecular Therapeutics Inc
$10.42+0.71 (+7.31%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving FDMT Today?
No stock-specific AI insight has been generated for FDMT yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$545M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume711K
Avg Volume (10D)—
Shares Outstanding52.3M
FDMT News
20 articles- 4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 7, 2026
- 4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming MilestonesYahoo Finance·May 7, 2026
- Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 7, 2026
- 4DMT to Participate in Upcoming Investor ConferencesYahoo Finance·May 4, 2026
- 4DMT Announces New Employment Inducement GrantsYahoo Finance·Apr 17, 2026
- electroCore (ECOR) Moves 7.1% Higher: Will This Strength Last?Yahoo Finance·Apr 10, 2026
- 4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat EstimatesYahoo Finance·Mar 18, 2026
- 4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming MilestonesYahoo Finance·Mar 18, 2026
- 4DMT to Participate in Upcoming Investor MeetingsYahoo Finance·Mar 16, 2026
- 4D Molecular Therapeutics Highlights 4D-150 Phase III Momentum, DME Plans, Cash Runway at Leerink ConferenceMarketbeat·Mar 16, 2026
- 4D Molecular Therapeutics Maps Phase 3 4D-150 Timeline, DME Expansion in Barclays Conference TalkMarketbeat·Mar 16, 2026
- Where is 4D Molecular Therapeutics (FDMT) Headed According to the Street?Yahoo Finance·Feb 28, 2026
- 4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMDYahoo Finance·Feb 9, 2026
- Barclays Flags M&A Tailwinds and Pricing Relief as Upside Catalysts for 4D Molecular Therapeutics, Inc. (FDMT)Yahoo Finance·Feb 2, 2026
- 4DMT Provides Company Update and Anticipated Development Milestones for 2026Yahoo Finance·Jan 7, 2026
- Why Everyone Is Watching 4D Molecular Therapeutics, Inc. (FDMT) CloselyYahoo Finance·Dec 27, 2025
- 4D Molecular Therapeutics, Inc.'s (NASDAQ:FDMT) institutional investors lost 20% over the past week but have profited from longer-term gainsYahoo Finance·Dec 23, 2025
- 4D Molecular Reports Positive Interim Early-Stage Data in Cystic Fibrosis Genetic Medicine Trial, Selects Mid-Stage DoseYahoo Finance·Dec 17, 2025
- 4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung DiseaseYahoo Finance·Dec 17, 2025
- 4DMT to Present at the 44th Annual J.P. Morgan Healthcare ConferenceYahoo Finance·Dec 8, 2025
All 20 articles loaded
Price Data
Open$9.55
Previous Close$9.71
Day High$9.86
Day Low$9.49
52 Week High—
52 Week Low—
Fundamentals
Market Cap$545M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume711K
Avg Volume (10D)—
Shares Outstanding52.3M
About 4D Molecular Therapeutics Inc
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
MaterialsBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
CIK—
Composite FIGI—
Share Class FIGI—